The best first line chemotherapy regimen for a patient with HER2+ breast cancer is now Herceptin + Perjeta + Docetaxel. The data was presented recently in Madrid at the European Cancer Conference (ESMO) as part of the CLEOPATRA study. The data revealed a nearly 17 month survival benefit!!
It is so rare to see such massive benefits in cancer treatments that it would be hard for funding agencies to ignore this data.
Well done to all the patients, their families, friends and all the medical personnel who made this possible in collaboration with the pharmaceutical companies.